Sentinel Lymph‑Node Biopsy or Targeted Axillary Dissection in Node‑Positive Breast Cancer Patients Submitted to Neoadjuvant Therapy?
Revista Portuguesa de Cirurgia · 08.10.2024
DOI: 10.34635/rpc.1074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Portuguesa de Cirurgia, erschienen am 08.10.2024. Verfasst von Sousa und 5 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Targeted axillary dissection (TAD) was designed for nodal staging in cN+ breast cancer (BC) patients submitted to neoadjuvant therapy (NAT). A recent study questioned the need to mark suspicious nodes pre-NAT. Methods: cT1-4 N1-2 BC patients scheduled for NAT were selected for retrospective appraisal. Patients were divided according with SLNB/TAD and ycN0/ycN+ status. Detection rate (DR), concordance rate (CR), predictive factors of successful clipped-node biopsy (CNB), sentinel node (SN) pathological complete response (pCR) and of additional non-sentinel lymph node (NSLN) involvement were assessed. Oncological outcomes were evaluated.
Results
The study included 85 consecutive patients. DR was 83.6%, 98.8% and 98.8% for CNB, SLNB and TAD, respectively. CNB did not drive management changes as every CN was sentinel (CR 100.0%). CNB was unsuccessful in 10 patients with 2 (20.0%) re-operated with no additional benefit. Removal of at least 3 SN was associated with successful CNB (p=0.001). Fewer (1 vs 2) suspicious nodes at diagnostic echography and triple-negative or HER2 biological subtype were predictive of SN pCR. Lymph-vascular invasion was predictive of additional NSLN involvement in pSN+ patients (p=0.008). Disease-free survival was worse in ypSN+ (p=0.029) and the only regional recurrence was in an axillary lymph node dissection (ALND) patient. There was no difference in the overall survival between ALND and no-ALND patients (p=0.270).
Conclusion
CNB is superfluous if 3 or more SN are retrieved using a dual mapping technique. It is safe to omit ALND if pCR of the SN is achieved. Future studies should assess the need for ALND in ypSN+ patients.
Schlagwörter
Zitieren
APA
Sousa, Nuno, Pinto, Catarina, Peleteiro, B., & Fougo, J. L. (2024). Sentinel Lymph‑Node Biopsy or Targeted Axillary Dissection in Node‑Positive Breast Cancer Patients Submitted to Neoadjuvant Therapy?. Revista Portuguesa de Cirurgia. https://doi.org/10.34635/rpc.1074
Vancouver
Sousa, Nuno, Pinto, Catarina, Peleteiro B, Fougo JL. Sentinel Lymph‑Node Biopsy or Targeted Axillary Dissection in Node‑Positive Breast Cancer Patients Submitted to Neoadjuvant Therapy?. Revista Portuguesa de Cirurgia. 2024. doi:10.34635/rpc.1074
BibTeX
@article{Sousa2024,
author = {Sousa and Nuno and Pinto and Catarina and Peleteiro, Bárbara and Fougo, José Luís},
title = {Sentinel Lymph‑Node Biopsy or Targeted Axillary Dissection in Node‑Positive Breast Cancer Patients Submitted to Neoadjuvant Therapy?},
journal = {Revista Portuguesa de Cirurgia},
year = {2024},
doi = {10.34635/rpc.1074}
}
EUVIMED